BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 11326893)

  • 1. [Protecting infection by using rhG-CSF in patients with lung cancer during chemotherapeutic courses].
    Zhang S; Liu X; Fang J
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jun; 21(6):355-7. PubMed ID: 11326893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of recombinant human granulocyte colony stimulating factor in children with acute myeloid leukemia.
    Shang X; Yin H; Lu A; Zhang L
    Chin Med J (Engl); 1999 Jul; 112(7):620-2. PubMed ID: 11601256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in white blood cells and myeloperoxidase activity in rhG-CSF prophylactic patients receiving cytotoxic chemotherapy.
    Charuruks N; Krailadsiri P; Voravud N; Nitipaijit N; Srisink N; Settapiboon R
    J Med Assoc Thai; 1994 Aug; 77(8):426-33. PubMed ID: 7533203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group.
    Ozkaynak MF; Krailo M; Chen Z; Feusner J
    Pediatr Blood Cancer; 2005 Sep; 45(3):274-80. PubMed ID: 15806544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
    Repetto L;
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
    Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
    Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokines in cancer chemotherapy: present state and problems in use of G- and GM-CSF for solid tumors in Japan].
    Ogawara M
    Gan To Kagaku Ryoho; 1998 Jan; 25(2):164-70. PubMed ID: 9474924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
    Shochat E; Rom-Kedar V
    Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer.
    Soda H; Oka M; Fukuda M; Kinoshita A; Sakamoto A; Araki J; Fujino S; Itoh N; Watanabe K; Kanda T; Nakano M; Hara K
    Cancer Chemother Pharmacol; 1996; 38(1):9-12. PubMed ID: 8603458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous granulocyte colony-stimulating factor (G-CSF) levels in chemotherapy-induced neutropenia and in neutropenia related with primary diseases.
    Kavgaci H; Ozdemir F; Aydin F; Yavuz A; Yavuz M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):475-9. PubMed ID: 12636092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of successful hypospadias repair without infection using recombinant human granulocyte-colony stimulating factor (rhG-CSF) for idiopathic neutropenia].
    Kojima Y; Hayashi Y; Umemoto Y; Sakakura T; Sasaki S; Kohri K; Kato F
    Hinyokika Kiyo; 1998 Jun; 44(6):419-21. PubMed ID: 9719943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW; Treish IM; Zaru L
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human granulocyte colony-stimulating factor for treatment of puppies with neutropenia secondary to canine parvovirus infection.
    Rewerts JM; McCaw DL; Cohn LA; Wagner-Mann C; Harrington D
    J Am Vet Med Assoc; 1998 Oct; 213(7):991-2. PubMed ID: 9776994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.